Home › Trials › NCT06712628

Comparing the effectiveness of Upadacitinib and TNF inhibitors for rheumatoid arthritis in Germany

Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING

Observational AbbVie · NCT06712628

This study is testing whether Upadacitinib works better than traditional TNF inhibitors for adults with moderate to severe rheumatoid arthritis in Germany.

Quick facts

Study typeObservational
Enrollment678 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsUpadacitinib
Locations53 sites (Freiburg im Breisgau, Baden-Wurttemberg and 52 other locations)
Trial IDNCT06712628 on ClinicalTrials.gov

What this trial studies

This observational study aims to compare the retention rates of Upadacitinib (UPA) versus tumor necrosis factor inhibitors (TNFi) in adult patients with moderate to severe active rheumatoid arthritis (RA) in Germany. Approximately 678 participants will be enrolled across 80 sites, with recruitment lasting around 24 months and participation lasting up to 24 months. The study will assess the effectiveness of these treatments as prescribed by physicians according to local standards of care.

Who should consider this trial

Good fit: Ideal candidates for this study are adults with a confirmed diagnosis of moderate to severe active rheumatoid arthritis who are starting treatment with either Upadacitinib or a TNF inhibitor.

Not a fit: Patients who have previously been treated with Upadacitinib or the same TNF inhibitor prescribed for this study will not benefit from participation.

Why it matters

Potential benefit: If successful, this study could provide insights into which treatment option offers better long-term retention for patients with moderate to severe rheumatoid arthritis.

How similar studies have performed: While this study is observational and focuses on real-world data, similar studies comparing treatment retention rates have shown promising results, indicating the potential for valuable insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician.
* Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study
* UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies

Exclusion Criteria:

* Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug \[whichever is longer\] prior to baseline)
* Prior treatment with Upadacitinib
* Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study

Where this trial is running

Freiburg im Breisgau, Baden-Wurttemberg and 52 other locations

+3 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisUpadacitinibTumor Necrosis Factor Inhibitor Treatment
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.